EUAA

Leading today. Redefining tomorrow.

Covers 740+ genes
and is the first to
unlock epigenomics1,2*

References

Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

Product availability may vary depending on region.

Powered by Guardant Infinityâ„¢

Highest sensitivity
with a reportable range
down to 0.001% MAF1

MAF, mutant allele fraction.
*Guardant360 Liquid is the first and only commercially available liquid biopsy to unlock genomics and epigenomics from a single input.
†Median turnaround time from sample receipt to results.

Home Oncology Portfolio Partnerships European Policy

Fast results
in 7 days1†

Infinity-powered
epigenomics & genomics